×
About 2,266 results
Screening for Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults: U...
https://doi.org/10.1001/jama.2018.14741
JAMA , Curry SJ et. al.

Oct 25th, 2018 - Intimate partner violence (IPV) and abuse of older or vulnerable adults are common in the United States but often remain undetected. In addition to the immediate effects of IPV, such as injury and death, there are other health consequences, many with long-term effects, including development of mental health conditions such as depression, posttraumatic stress disorder, anxiety disorders, substan...

Pelvic Organ Prolapse ACOG Practice Bulletin, Number 214
https://journals.lww.com/greenjournal/Abstract/2019/11000/Pelvic_Organ_Prolapse__ACOG_Practice_Bulletin,.44.aspx
Obstetrics & Gynecology;

Nov 29th, 2019 - Pelvic organ prolapse (POP) is a common, benign condition in women. For many women it can cause vaginal bulge and pressure, voiding dysfunction, defecatory dysfunction, and sexual dysfunction, which may adversely affect quality of life. Women in the United States have a 13% lifetime risk of undergoing surgery for POP (1). Although POP can occur in younger women, the peak incidence of POP sympto...

Study Finds Sexual Health Issues Are a Concern Among Majority of Women With Breast Cancer
https://ascopost.com/news/november-2019/study-finds-sexual-health-issues-are-a-concern-among-majority-of-women-with-breast-cancer/
ASCO Post; Doyle C

Nov 17th, 2019 - Endocrine therapy has been a lifesaver for women with estrogen receptor–positive breast cancer, but decreases in recurrence and cancer-related mortality have come with substantial side effects, according to data presented at the 2019 Supportive Care in Oncology Symposium.1 The results of a cross-sectional retrospective study have underscored genitourinary symptoms and sexual health concerns exp...

Depression in Children and Adolescents: Evaluation and Treatment
https://www.aafp.org/afp/2019/1115/p609.html
American Family Physician; Selph SS et al

Nov 16th, 2019 - he prevalence of major unipolar depression in children and adolescents is increasing in the United States. In 2016, approximately 5% of 12-year-olds and 17% of 17-year-olds reported experiencing a major depressive episode in the previous 12 months. Screening for depression in adolescents 12 years and older should be conducted annually using a validated instrument, such as the Patient Health Que...

Best, Worst, and Typical Cancer Survival: New Estimates Tool
https://www.medscape.com/viewarticle/921425
Medscape O'Brien K

Nov 14th, 2019 - "How much time have I got, Doc?" That's a question never far from the mind of most metastatic breast cancer patients. Unfortunately, accurate estimates are elusive. A new approach mitigates the difficulty of that tough task by offering not one but three estimates.

Risk-Adapted Starting Age of Screening for Relatives of Patients With Breast Cancer
https://jamanetwork.com/journals/jamaoncology/article-abstract/2755638
JAMA Oncology; Mukama T, et al

Nov 13th, 2019 - At what age should women with differing family histories of breast cancer start screening?

Is There a Difference in Breast Cancer Recurrence Rates After Surgery With Regional vs General Anesthesia?
https://ascopost.com/news/november-2019/is-there-a-difference-in-breast-cancer-recurrence-rates-after-surgery-with-regional-vs-general-anesthesia/
ASCO Post; Stenger M

Nov 11th, 2019 - In a trial reported in The Lancet, Sessler et al found no difference in breast cancer recurrence after surgery with regional anesthesia-analgesia using paravertebral block and propofol vs general anesthesia with the volatile anesthetic sevoflurane and opioid analgesia. They also found no difference in persistent incisional pain between approaches.

Top 10 Medical Innovations for 2020, According to Cleveland Clinic
https://www.medscape.com/viewarticle/920936
Medscape

Nov 9th, 2019 - A dual-acting osteoporosis drug, minimally invasive mitral valve surgery, and a new treatment for peanut allergies are among the medical advances that will significantly transform the medical field and improve care for patients in the coming year, according to the Cleveland Clinic's list of top 10 medical innovations for 2020.

PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets
https://ascopost.com/issues/november-10-2019/prima-trial-reports-benefit-with-niraparib-across-ovarian-cancer-subsets/
ASCO Post; Helwick C

Nov 9th, 2019 - In women with advanced ovarian cancer responding to first-line chemotherapy, maintenance therapy with the PARP inhibitor niraparib significantly reduced the risk of disease progression by 38% overall and by 60% in women with BRCA mutations. Even patients without a homologous recombination deficiency derived advantage from this treatment, in the phase III PRIMA/ENGOT-OV26/GOG-3012 trial presente...

Men With BRCA2 Should Be Screened for Prostate Cancer
https://www.medscape.com/viewarticle/921000
Medscape Davenport L

Nov 7th, 2019 - Men who carry the BRCA2 gene mutation, which is linked to breast and ovarian cancer, are at risk of developing aggressive prostate cancer and so should undergo regular prostate-specific antigen (PSA) testing, suggest findings from a major study.

Clinicians’ Perspectives on Barriers to Discussing Infertility and Fertility Preservation With Young Women With Cancer
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2753979
JAMA Network Open; Covelli A, et al

Nov 5th, 2019 - What do clinicians perceive as barriers to engaging in fertility preservation discussions with young women with cancer?

Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial
https://ascopubs.org/doi/abs/10.1200/JCO.19.00693
Journal of Clinical Oncology; Sharma, P. et. al.

Oct 27th, 2019 - PURPOSE To independently validate two biomarkers, a 44-gene DNA damage immune response (DDIR) signature and stromal tumor-infiltrating lymphocytes (sTILs), as prognostic markers in patients with triple-negative breast cancer (TNBC) treated with adjuvant doxorubicin (A) and cyclophosphamide (C) in SWOG 9313. METHODS Four hundred twenty-five centrally determined patient cases with TNBC from ...

Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials
https://jnnp.bmj.com/content/early/2019/08/29/jnnp-2019-320912
Journal of Neurology, Neurosurgery, & Psychiatry; Bai. S., et al

Oct 27th, 2019 - Objectives To systematically review the efficacy and safety of anti-inflammatory agents for patients with major depressive disorders. Methods We searched the literature to identify potentially relevant randomised controlled trials (RCTs) up to 1 January 2019. The primary outcome was efficacy, measured by mean changes in depression score from baseline to endpoint. Secondary outcomes included ...

FDA approves niraparib for HRD-positive advanced ovarian cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer

Oct 22nd, 2019 - On October 23, 2019,the Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status. HRD is defined by either a deleterious or suspected deleterious BRCA mu...

2019 Supportive Care: Anxiety, Depression, and Low Social Support Are Significant Factors in Cancer Pain Intensity
https://ascopost.com/news/october-2019/anxiety-depression-and-low-social-support-are-significant-factors-in-cancer-pain-intensity/

Oct 21st, 2019 - Pain is one of the most common symptoms associated with cancer and its treatment, and feelings of anxiety and depression can intensify the level of pain patients experience, according to the results from a study by Galloway et al that will be presented at the 2019 Supportive Care in Oncology Symposium (Abstract 76). However, authors also reported that having greater social support can help miti...

ASCO Breakthrough: Breast Cancer Gene Expression Signature May Help Predict Recurrence Postradiotherapy
https://ascopost.com/news/october-2019/breast-cancer-gene-expression-signature-may-help-to-predict-recurrence-postradiotherapy/

Oct 13th, 2019 - Researchers have identified a gene pattern that may help predict which patients with breast cancer will have early or late disease recurrence following radiation therapy. The ability to predict the timing of recurrence could change—and improve—treatment strategies and determine the length of follow-up needed. These findings were presented by Speers et al at ASCO Breakthrough: A Global Summit fo...

Do High-Dose Statins Increase the Risk for Osteoporosis?
https://www.medscape.com/viewarticle/919825

Oct 13th, 2019 - The protective effect of statin therapy on bone health that has been demonstrated in some studies may be dose-related, and although low doses are associated with a reduced risk for osteoporosis, high doses were linked to an increased risk of the bone disease in new research.

Following NCCN Guidelines for Metastatic Breast Cancer Results in Lower Costs for Patients, According to New Study
https://www.nccn.org/about/news/newsinfo.aspx?NewsID=1712

Oct 9th, 2019 - A new study from the O’Neal Comprehensive Cancer Center at University of Alabama at Birmingham (UAB), published in the October 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network, finds that direct costs for metastatic breast cancer (MBC) patients increase dramatically when their treatment differs from recommendations in the NCCN Clinical Practice Guidelines in Oncology (N...

Recent Trends in the Treatment and Prognosis of Male Breast Cancer
https://ascopost.com/news/october-2019/recent-trends-in-the-treatment-and-prognosis-of-male-breast-cancer/

Oct 8th, 2019 - A recent analysis published by Yadav et al in Cancer reviewed how the treatment of male breast cancer has evolved over the years 2004 to 2014. In addition, certain patient-, tumor-, and treatment-related factors were found to be linked with better survival.

Cervical Cancer Screening (PDQ®)–Health Professional Version
https://www.cancer.gov/types/cervical/hp/cervical-screening-pdq

Oct 4th, 2019 - Based on solid evidence, regular screening of appropriate women for cervical cancer with the Pap test reduces mortality from cervical cancer. The benefits of screening women younger than 21 years are small because of the low prevalence of lesions that will progress to invasive cancer. Screening is not beneficial in women older than 65 years if they have had a recent history of negative test res...